Ruxolitinib View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018-08-02

AUTHORS

Stefanie Ajayi , Heiko Becker , Heike Reinhardt , Monika Engelhardt , Robert Zeiser , Nikolas von Bubnoff , Ralph Wäsch

ABSTRACT

Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis (MF) by the US Food and Drug Administration (FDA) in 2011 and by the European Medicines Agency (EMA) in 2012, followed by the approval for the treatment of hydroxyurea (HU)-resistant or -intolerant polycythemia vera (PV) in 2014. Both MF and PV are myeloproliferative neoplasms (MPNs) which are characterized by the aberrant activation of the JAK–STAT pathway. Clinically, MF features bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality-of-life through associated symptoms. PV is characterized by the overproduction of primarily red blood cells (RBC), risk of thrombotic complications, and development of secondary MF. Ruxolitinib treatment results in a meaningful reduction in spleen size and symptom burden in the majority of MF patients and may also have a favorable effect on survival. In PV, ruxolitinib effectively controls the hematocrit and reduces splenomegaly. Since recently, ruxolitinib is also under investigation for the treatment of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Toxicities of ruxolitinib include myelosuppression, which results in dose-limiting thrombocytopenia and anemia, and viral reactivations. The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors. Several further JAK inhibitors are currently under investigation for MPNs or other immuno-inflammatory diseases. More... »

PAGES

119-132

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-91439-8_6

DOI

http://dx.doi.org/10.1007/978-3-319-91439-8_6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105946592

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30069628


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Janus Kinase 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Janus Kinase 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polycythemia Vera", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Primary Myelofibrosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spleen", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany", 
            "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ajayi", 
        "givenName": "Stefanie", 
        "id": "sg:person.016630320514.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016630320514.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany", 
            "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Becker", 
        "givenName": "Heiko", 
        "id": "sg:person.0631556757.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631556757.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany", 
            "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reinhardt", 
        "givenName": "Heike", 
        "id": "sg:person.0650617065.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650617065.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany", 
            "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Engelhardt", 
        "givenName": "Monika", 
        "id": "sg:person.01216502565.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216502565.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany", 
            "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zeiser", 
        "givenName": "Robert", 
        "id": "sg:person.01063164407.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063164407.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany", 
            "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "von Bubnoff", 
        "givenName": "Nikolas", 
        "id": "sg:person.0662205755.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662205755.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany", 
            "Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "W\u00e4sch", 
        "givenName": "Ralph", 
        "id": "sg:person.01151333006.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151333006.25"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-08-02", 
    "datePublishedReg": "2018-08-02", 
    "description": "Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis (MF) by the US Food and Drug Administration (FDA) in 2011 and by the European Medicines Agency (EMA) in 2012, followed by the approval for the treatment of hydroxyurea (HU)-resistant or -intolerant polycythemia vera (PV) in 2014. Both MF and PV are myeloproliferative neoplasms (MPNs) which are characterized by the aberrant activation of the JAK\u2013STAT pathway. Clinically, MF features bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality-of-life through associated symptoms. PV is characterized by the overproduction of primarily red blood cells (RBC), risk of thrombotic complications, and development of secondary MF. Ruxolitinib treatment results in a meaningful reduction in spleen size and symptom burden in the majority of MF patients and may also have a favorable effect on survival. In PV, ruxolitinib effectively controls the hematocrit and reduces splenomegaly. Since recently, ruxolitinib is also under investigation for the treatment of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Toxicities of ruxolitinib include myelosuppression, which results in dose-limiting thrombocytopenia and anemia, and viral reactivations. The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors. Several further JAK inhibitors are currently under investigation for MPNs or other immuno-inflammatory diseases.", 
    "editor": [
      {
        "familyName": "Martens", 
        "givenName": "Uwe M.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-91439-8_6", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-91438-1", 
        "978-3-319-91439-8"
      ], 
      "name": "Small Molecules in Hematology", 
      "type": "Book"
    }, 
    "keywords": [
      "hematopoietic stem cell transplantation", 
      "polycythemia vera", 
      "European Medicines Agency", 
      "myeloproliferative neoplasms", 
      "red blood cells", 
      "allogeneic hematopoietic stem cell transplantation", 
      "intolerant polycythemia vera", 
      "treatment of graft", 
      "immuno-inflammatory diseases", 
      "stem cell transplantation", 
      "dose-limiting thrombocytopenia", 
      "selective oral inhibitor", 
      "treatment of myelofibrosis", 
      "bone marrow fibrosis", 
      "potent CYP3A4 inhibitor", 
      "abnormal blood counts", 
      "treatment of hydroxyurea", 
      "host disease", 
      "thrombotic complications", 
      "symptom burden", 
      "oral inhibitor", 
      "MF patients", 
      "blood count", 
      "cell transplantation", 
      "viral reactivation", 
      "marrow fibrosis", 
      "CYP3A4 inhibitors", 
      "spleen size", 
      "secondary myelofibrosis", 
      "JAK inhibitors", 
      "US Food", 
      "Drug Administration", 
      "ruxolitinib", 
      "Medicines Agency", 
      "myelofibrosis", 
      "treatment results", 
      "JAK-STAT pathway", 
      "aberrant activation", 
      "meaningful reduction", 
      "blood cells", 
      "favorable effect", 
      "treatment", 
      "disease", 
      "inhibitors", 
      "kinase 1", 
      "poor quality", 
      "myelosuppression", 
      "thrombocytopenia", 
      "splenomegaly", 
      "complications", 
      "patients", 
      "transplantation", 
      "INCB018424", 
      "fibrosis", 
      "anemia", 
      "neoplasms", 
      "graft", 
      "symptoms", 
      "hematocrit", 
      "CYP3A4", 
      "administration", 
      "survival", 
      "burden", 
      "risk", 
      "hydroxyurea", 
      "vera", 
      "JAK2", 
      "toxicity", 
      "approval", 
      "activation", 
      "count", 
      "reactivation", 
      "cells", 
      "overproduction", 
      "majority", 
      "pathway", 
      "metabolization", 
      "food", 
      "life", 
      "investigation", 
      "reduction", 
      "effect", 
      "quality", 
      "development", 
      "results", 
      "size", 
      "agencies"
    ], 
    "name": "Ruxolitinib", 
    "pagination": "119-132", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105946592"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-91439-8_6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30069628"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-91439-8_6", 
      "https://app.dimensions.ai/details/publication/pub.1105946592"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-11-24T21:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/chapter/chapter_467.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-91439-8_6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-91439-8_6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-91439-8_6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-91439-8_6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-91439-8_6'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      22 PREDICATES      123 URIs      116 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-91439-8_6 schema:about N3032a8adf2f040bcbed35a5e2166d9c3
2 N477b1d53dc6b4fdbad2a362fad5ea47b
3 N5d21925a4594413e9ad322baca386ba8
4 N6034640ec3c54d7c92c397c10584bcfa
5 N63b8b1fde9e44b1eace25be5847276c5
6 Na13b6bffe0514a208dc28000346db67e
7 Nb0c6d79f71dd489db67b7e120d0f621d
8 Nb0f2ef4bc9f54cb8bab413cf600c7815
9 Nf8000cb3d02342dc8c0d88c14906b1db
10 Nf9781d25612a4cdda65979a4511049a3
11 Nfe79ea48d22d4e7189ea8821b3dbef18
12 anzsrc-for:11
13 anzsrc-for:1102
14 schema:author N15763c9f5ec9482c9aa5bfc354f8b6da
15 schema:datePublished 2018-08-02
16 schema:datePublishedReg 2018-08-02
17 schema:description Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis (MF) by the US Food and Drug Administration (FDA) in 2011 and by the European Medicines Agency (EMA) in 2012, followed by the approval for the treatment of hydroxyurea (HU)-resistant or -intolerant polycythemia vera (PV) in 2014. Both MF and PV are myeloproliferative neoplasms (MPNs) which are characterized by the aberrant activation of the JAK–STAT pathway. Clinically, MF features bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality-of-life through associated symptoms. PV is characterized by the overproduction of primarily red blood cells (RBC), risk of thrombotic complications, and development of secondary MF. Ruxolitinib treatment results in a meaningful reduction in spleen size and symptom burden in the majority of MF patients and may also have a favorable effect on survival. In PV, ruxolitinib effectively controls the hematocrit and reduces splenomegaly. Since recently, ruxolitinib is also under investigation for the treatment of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Toxicities of ruxolitinib include myelosuppression, which results in dose-limiting thrombocytopenia and anemia, and viral reactivations. The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors. Several further JAK inhibitors are currently under investigation for MPNs or other immuno-inflammatory diseases.
18 schema:editor N9058daff51c2434e86f2fb17f1f1eced
19 schema:genre chapter
20 schema:isAccessibleForFree false
21 schema:isPartOf N5b667ce23441479b9550b5c76de72141
22 schema:keywords CYP3A4
23 CYP3A4 inhibitors
24 Drug Administration
25 European Medicines Agency
26 INCB018424
27 JAK inhibitors
28 JAK-STAT pathway
29 JAK2
30 MF patients
31 Medicines Agency
32 US Food
33 aberrant activation
34 abnormal blood counts
35 activation
36 administration
37 agencies
38 allogeneic hematopoietic stem cell transplantation
39 anemia
40 approval
41 blood cells
42 blood count
43 bone marrow fibrosis
44 burden
45 cell transplantation
46 cells
47 complications
48 count
49 development
50 disease
51 dose-limiting thrombocytopenia
52 effect
53 favorable effect
54 fibrosis
55 food
56 graft
57 hematocrit
58 hematopoietic stem cell transplantation
59 host disease
60 hydroxyurea
61 immuno-inflammatory diseases
62 inhibitors
63 intolerant polycythemia vera
64 investigation
65 kinase 1
66 life
67 majority
68 marrow fibrosis
69 meaningful reduction
70 metabolization
71 myelofibrosis
72 myeloproliferative neoplasms
73 myelosuppression
74 neoplasms
75 oral inhibitor
76 overproduction
77 pathway
78 patients
79 polycythemia vera
80 poor quality
81 potent CYP3A4 inhibitor
82 quality
83 reactivation
84 red blood cells
85 reduction
86 results
87 risk
88 ruxolitinib
89 secondary myelofibrosis
90 selective oral inhibitor
91 size
92 spleen size
93 splenomegaly
94 stem cell transplantation
95 survival
96 symptom burden
97 symptoms
98 thrombocytopenia
99 thrombotic complications
100 toxicity
101 transplantation
102 treatment
103 treatment of graft
104 treatment of hydroxyurea
105 treatment of myelofibrosis
106 treatment results
107 vera
108 viral reactivation
109 schema:name Ruxolitinib
110 schema:pagination 119-132
111 schema:productId N357806a372b845b5aad6f2db10bbd868
112 N8096dda3d3654968b0e1a59f81c0140e
113 Nb3aba5ca965c42529ac0791aa9687ddc
114 schema:publisher Na0e47736568f4a239c22cb632e6cb49d
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105946592
116 https://doi.org/10.1007/978-3-319-91439-8_6
117 schema:sdDatePublished 2022-11-24T21:19
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher Ncd65d961ec614be0861e9df759700b06
120 schema:url https://doi.org/10.1007/978-3-319-91439-8_6
121 sgo:license sg:explorer/license/
122 sgo:sdDataset chapters
123 rdf:type schema:Chapter
124 N15763c9f5ec9482c9aa5bfc354f8b6da rdf:first sg:person.016630320514.38
125 rdf:rest Ncb4bf85bd0244da88ce2630b80d59c95
126 N3032a8adf2f040bcbed35a5e2166d9c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Pyrazoles
128 rdf:type schema:DefinedTerm
129 N357806a372b845b5aad6f2db10bbd868 schema:name pubmed_id
130 schema:value 30069628
131 rdf:type schema:PropertyValue
132 N477b1d53dc6b4fdbad2a362fad5ea47b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Polycythemia Vera
134 rdf:type schema:DefinedTerm
135 N5b667ce23441479b9550b5c76de72141 schema:isbn 978-3-319-91438-1
136 978-3-319-91439-8
137 schema:name Small Molecules in Hematology
138 rdf:type schema:Book
139 N5d21925a4594413e9ad322baca386ba8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Janus Kinase 2
141 rdf:type schema:DefinedTerm
142 N6034640ec3c54d7c92c397c10584bcfa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Protein Kinase Inhibitors
144 rdf:type schema:DefinedTerm
145 N63b8b1fde9e44b1eace25be5847276c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Janus Kinase 1
147 rdf:type schema:DefinedTerm
148 N662ab503a45a4af69c45d116c7647ff5 rdf:first sg:person.01151333006.25
149 rdf:rest rdf:nil
150 N7160f376b0a841e6b0955aff65f3f155 schema:familyName Martens
151 schema:givenName Uwe M.
152 rdf:type schema:Person
153 N7c01796c55454dc7977023b586f1e56b rdf:first sg:person.0662205755.90
154 rdf:rest N662ab503a45a4af69c45d116c7647ff5
155 N8096dda3d3654968b0e1a59f81c0140e schema:name dimensions_id
156 schema:value pub.1105946592
157 rdf:type schema:PropertyValue
158 N9058daff51c2434e86f2fb17f1f1eced rdf:first N7160f376b0a841e6b0955aff65f3f155
159 rdf:rest rdf:nil
160 Na0e47736568f4a239c22cb632e6cb49d schema:name Springer Nature
161 rdf:type schema:Organisation
162 Na13b6bffe0514a208dc28000346db67e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Humans
164 rdf:type schema:DefinedTerm
165 Na89cf9e4ab8841bba1ffd55dd2c9f4dd rdf:first sg:person.01216502565.63
166 rdf:rest Nd6600527acaf4716af231ae58509c78f
167 Nb0c6d79f71dd489db67b7e120d0f621d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Antineoplastic Agents
169 rdf:type schema:DefinedTerm
170 Nb0f2ef4bc9f54cb8bab413cf600c7815 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Primary Myelofibrosis
172 rdf:type schema:DefinedTerm
173 Nb3aba5ca965c42529ac0791aa9687ddc schema:name doi
174 schema:value 10.1007/978-3-319-91439-8_6
175 rdf:type schema:PropertyValue
176 Ncb4bf85bd0244da88ce2630b80d59c95 rdf:first sg:person.0631556757.06
177 rdf:rest Ndabb0b2ce87341a09f57fcbea96b8bf4
178 Ncd65d961ec614be0861e9df759700b06 schema:name Springer Nature - SN SciGraph project
179 rdf:type schema:Organization
180 Nd6600527acaf4716af231ae58509c78f rdf:first sg:person.01063164407.39
181 rdf:rest N7c01796c55454dc7977023b586f1e56b
182 Ndabb0b2ce87341a09f57fcbea96b8bf4 rdf:first sg:person.0650617065.92
183 rdf:rest Na89cf9e4ab8841bba1ffd55dd2c9f4dd
184 Nf8000cb3d02342dc8c0d88c14906b1db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Spleen
186 rdf:type schema:DefinedTerm
187 Nf9781d25612a4cdda65979a4511049a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Pyrimidines
189 rdf:type schema:DefinedTerm
190 Nfe79ea48d22d4e7189ea8821b3dbef18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Nitriles
192 rdf:type schema:DefinedTerm
193 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
194 schema:name Medical and Health Sciences
195 rdf:type schema:DefinedTerm
196 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
197 schema:name Cardiorespiratory Medicine and Haematology
198 rdf:type schema:DefinedTerm
199 sg:person.01063164407.39 schema:affiliation grid-institutes:None
200 schema:familyName Zeiser
201 schema:givenName Robert
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063164407.39
203 rdf:type schema:Person
204 sg:person.01151333006.25 schema:affiliation grid-institutes:None
205 schema:familyName Wäsch
206 schema:givenName Ralph
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151333006.25
208 rdf:type schema:Person
209 sg:person.01216502565.63 schema:affiliation grid-institutes:None
210 schema:familyName Engelhardt
211 schema:givenName Monika
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216502565.63
213 rdf:type schema:Person
214 sg:person.016630320514.38 schema:affiliation grid-institutes:None
215 schema:familyName Ajayi
216 schema:givenName Stefanie
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016630320514.38
218 rdf:type schema:Person
219 sg:person.0631556757.06 schema:affiliation grid-institutes:None
220 schema:familyName Becker
221 schema:givenName Heiko
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631556757.06
223 rdf:type schema:Person
224 sg:person.0650617065.92 schema:affiliation grid-institutes:None
225 schema:familyName Reinhardt
226 schema:givenName Heike
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650617065.92
228 rdf:type schema:Person
229 sg:person.0662205755.90 schema:affiliation grid-institutes:None
230 schema:familyName von Bubnoff
231 schema:givenName Nikolas
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662205755.90
233 rdf:type schema:Person
234 grid-institutes:None schema:alternateName Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany
235 schema:name Comprehensive Cancer Center Freiburg (CCCF), Hugstetter Str. 55, 79106, Freiburg, Germany
236 Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...